Sign up to save your podcasts
Or
Share Experts Talk CLL #8 : Data from the EHA and their Significance to Canadian Practice
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Experts Talk CLL #8 : Data from the EHA and their Significance to Canadian Practice
A discussion between Dr. Peter Anglin and Dr. Carolyn Owen (July 2022)
Dr. Anglin and Dr. Owen discuss evidence presented at the EHA 2022 and the impact of the presented data on Canadian routine practice and the management of CLL. The main focus is on trials in the first line setting – ELEVATE-TN with acalabrutinib and CLL14 AND CLL13 with venetoclax-based therapies. Dr. Anglin and Dr. Owen also touch on emerging options for relapsed/refractory disease, in particular, non-covalent (reversible) BTK inhibitor pirtobrutinib (LOXO-305).
Peter Anglin, MD, FRCPC, MBA, Hematologist/Oncologist, Physician Lead, Stronach Regional Cancer, Centre Newmarket, ON
Carolyn Owen, MD, MDres(UK), FRCPC, Hematologist, Tom Baker Cancer Centrex, Associate Professor, Division of Hematology & Hematological Malignancies, Tom Baker Cancer Centre, University of Calgary, Local Principal Investigator, Tom Baker Cancer Centre
This podcast is intended for Healthcare Professionals only. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities. This program was made possible through Master Clinician Alliance, which graciously acknowledges the educational grant and in-kind support provided by AbbVie Corporation.
View all episodes
By Various Topics on AML and CLL ManagementA discussion between Dr. Peter Anglin and Dr. Carolyn Owen (July 2022)
Dr. Anglin and Dr. Owen discuss evidence presented at the EHA 2022 and the impact of the presented data on Canadian routine practice and the management of CLL. The main focus is on trials in the first line setting – ELEVATE-TN with acalabrutinib and CLL14 AND CLL13 with venetoclax-based therapies. Dr. Anglin and Dr. Owen also touch on emerging options for relapsed/refractory disease, in particular, non-covalent (reversible) BTK inhibitor pirtobrutinib (LOXO-305).
Peter Anglin, MD, FRCPC, MBA, Hematologist/Oncologist, Physician Lead, Stronach Regional Cancer, Centre Newmarket, ON
Carolyn Owen, MD, MDres(UK), FRCPC, Hematologist, Tom Baker Cancer Centrex, Associate Professor, Division of Hematology & Hematological Malignancies, Tom Baker Cancer Centre, University of Calgary, Local Principal Investigator, Tom Baker Cancer Centre
This podcast is intended for Healthcare Professionals only. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities. This program was made possible through Master Clinician Alliance, which graciously acknowledges the educational grant and in-kind support provided by AbbVie Corporation.